In commercial broiler and layer operations where medication is delivered through nipple drinker lines, andrographolides veterinary grade API is most commonly converted into a water-soluble powder or concentrated drinking-water solution because oral gavage or individual injection is not practical under high-density housing. The formulation addition ratio is defined by final drinking-water concentration rather than feed inclusion; a 10% andrographolide water-soluble powder dosed at 1 kg per 1000 L drinking water yields 100 mg/L API, while a 5% powder requires 2 kg per 1000 L to achieve the same concentration. Manufacturing of the powder begins with spray-dried carrier granulation on a co-current rotary atomizer operated at inlet 160–180 °C and outlet 65–75 °C, using maltodextrin or lactose as the water-soluble carrier and silicon dioxide as an anti-caking agent; the API is dissolved or dispersed with carrier and then dry-blended to homogeneity in a ribbon blender before sifting through 40–80 mesh. Downstream production of the liquid oral concentrate involves dissolving the API in a co-solvent system of propylene glycol and purified water at pH 6.0–6.8, followed by clarification through a 1 µm polypropylene filter and filling into opaque HDPE containers. Compliance for this application falls under Regulation (EU) 2019/4 on medicated feed for water medication, with residual solvent limits per VICH GL18 class 3 solvents not more than 5000 ppm and heavy metals tested according to the pharmacopoeial monograph for the source plant extract. The terminal finished products are 5% and 10% water-soluble powders and oral solutions intended for flock administration; operational limitations include hard water above 250 mg/L CaCO₃, which can reduce solubility and should be chelated with citric acid before mixing.

Can Andrographolide Withstand Twin-Screw Wet Granulation for Swine Feed Premix Carriers?

Wet granulation of an andrographolide premix imposes simultaneous exposure to moisture, shear and temperature that accelerates lactone hydrolysis if the barrel set point is not controlled below 45 °C. In grower-finisher swine feed, the addition ratio is typically expressed as 100–200 mg/kg andrographolide in complete feed; a 1% premix would therefore be incorporated at 10–20 kg/tonne feed. Production starts with dry blending of the API into a corn cob or rice hull carrier in a horizontal ribbon blender of 600–1000 kg capacity for 15–20 min, after which a binder solution of polyvinylpyrrolidone K30 at 3–5% w/w is sprayed to achieve the wet mass endpoint. The wet mass is processed on a twin-screw extruder with L/D 16:1–20:1, screw speed 80–150 rpm, and jacket temperature 35–45 °C; die plate temperature must not exceed 40 °C under pressure of 10–25 bar to avoid darkening of lactose carriers and charring of the rice hull fraction. Extrudates are dried in a fluid bed dryer at inlet 55–65 °C to final moisture ≤5% by Karl Fischer titration per USP <921>, then sieved to 16–40 mesh for uniform granule size. Compliance requires impurity profiling under VICH GL11, total aerobic microbial count ≤10⁴ CFU/g, and absence of Salmonella in 25 g per ISO 4833-1 and ISO 6579-1; documentation must also meet Regulation (EU) 2019/4 carryover limits for medicated feed. Terminal product types are swine feed premix and oral granules for on-farm mixing or top dressing.

Injectable Aqueous Formulation: Co-Solvent Ratio, pH Drift, and Sterile Filtration Limits

The low aqueous solubility of andrographolide, a labdane diterpene lactone with molecular weight 350.45 g/mol, makes injectable formulation dependent on binary or ternary co-solvent systems rather than simple phosphate-buffered saline. A representative injectable composition contains 10–50 g/L andrographolide, 20–50% v/v propylene glycol, 10–30% v/v ethanol, and 10 mM phosphate buffer adjusted to pH 6.0–6.8; above pH 8.0, the butenolide lactone ring undergoes hydrolysis, and published data for specific degradation kinetics in veterinary injectable storage is limited. Downstream production begins with nitrogen-sparged dissolution of the API in the co-solvent phase under agitation at 20–25 °C, followed by addition of buffer, pH adjustment with dilute phosphoric acid or sodium hydroxide, and batch volume makeup. The solution is then filtered through 0.45 µm and 0.22 µm PVDF membrane filters with integrity testing before aseptic filling into amber glass ampoules of 10 mL or 20 mL. Terminal moist-heat sterilization at 121 °C for 15 min is only acceptable when terminal stability data confirm andrographolide assay loss ≤5%; otherwise, sterile filtration with aseptic processing is mandatory. The finished product is a veterinary injectable solution for intramuscular or subcutaneous administration in cattle and swine. Table 1 lists the critical compliance tests.

For companion animal fixed-dose formats, direct compression is rarely viable because the API exhibits poor flow and low bulk density; wet granulation is therefore the standard route for tablets and capsules. The addition ratio is expressed as API per dosage unit rather than feed concentration, commonly 25 mg, 50 mg, or 100 mg andrographolide per tablet, or 20–40% w/w API in capsule fill weights of 100–250 mg. Granulation uses microcrystalline cellulose PH101 as a filler, crospovidone 2–5% w/w as disintegrant, and povidone K30 at 3–5% w/w dissolved in water as the binder; the wet mass is passed through an oscillating granulator fitted with a 0.8–1.2 mm screen, dried in a tray oven or fluid bed at 45–55 °C to moisture 2–4% by USP <921>, and milled before blending with sodium starch glycolate 2–5% w/w and magnesium stearate 0.5–1.0% w/w. Tablets are compressed on a rotary tablet press at 10–20 kN to hardness 40–70 N, with friability less than 1.0% per USP <1216> and disintegration time ≤15 min in water at 37 °C per USP <701>. Capsule filling uses an automatic dosator machine with powder bed temperature maintained below 25 °C and relative humidity below 40% RH to prevent sticking. Compliance falls under FDA 21 CFR 210/211 current good manufacturing practices for finished pharmaceuticals and USP <905> uniformity of dosage units with acceptance value ≤15; the API must also comply with residual solvent limits under VICH GL18 and microbial limits for oral dosage forms. Terminal finished product types are uncoated or film-coated tablets and two-piece hard gelatin or hypromellose capsules for companion animal patients.

When Barrel Temperature Exceeds 40°C in Ruminant Oral Granule Lines

Ruminant oral granules present a narrower thermal window than poultry powders because molasses-based carriers and lignosulfonate binders plasticize above 40 °C, causing die blockage and non-uniform distribution of the API. The formulation addition ratio for adult cattle is commonly 0.5–2.0 g andrographolide per head per day, achieved with an oral granule containing 10–20% w/w API so that a single dose weighs 5–10 g. Process equipment consists of a low-shear plough mixer for premixing the API with calcium carbonate, wheat bran and molasses at 8–12% w/w, followed by a low-temperature pellet mill equipped with a 3–5 mm die and a product temperature sensor placed at the die outlet. Barrel and die temperature are maintained at 35–40 °C; if the temperature exceeds 40 °C, molasses viscosity drops and binder migration to the granule surface occurs, producing hard, glossy granules with delayed disintegration in ruminal fluid. Drying in a belt dryer with inlet air 45–50 °C for 20–40 min reduces moisture to ≤6% without causing API decomposition. Compliance for this oral dosage form references VICH GL18 for residual solvents, Regulation (EU) 2019/4 for medicated feed where applicable, and ISO 22000 prerequisite programs for feed safety in on-farm mixing; heavy metal limits follow the supplier pharmacopoeial monograph and should be verified with inductively coupled plasma mass spectrometry. Terminal product types are oral granules, drench powders and preweighed sachets for cattle, sheep and goats, with the operational precaution that simultaneous administration with alkaline oral rehydration solutions should be avoided because lactone ring stability is compromised above pH 8.0.

Extruded Aquafeed Pellets Leach Water-Soluble Actives Unless Lipophilic Barrier Coating Is Applied

Post-extrusion vacuum coating is the only industrial route that preserves andrographolide in aquafeed because the high barrel temperatures of 85–95 °C used in fish feed extrusion reduce assay recovery when the API is mixed into the meal before processing. The formulation addition ratio for aquaculture premix is usually 100–300 mg/kg finished feed, with the premix diluted before coating at 1–2 kg/tonne depending on premix strength. In this process, the API is pre-dispersed in fish oil or soybean oil at 25–35 °C with intensive rotor-stator mixing at 3000–6000 rpm to form a suspension, then applied to cooled extruded pellets under vacuum pressure of 0.4–0.6 bar in a vacuum coater. The oil layer acts as both lipophilic barrier and palatability mask; without this top-coat, water immersion of uncoated pellets results in rapid leaching of the water-soluble carrier fraction and loss of API to the tank water within 30–60 min. The terminal product types are floating, slow-sinking or sinking extruded pellets and premix powders for farm feed manufacturers. Compliance is governed by Regulation (EU) 2019/4 for medicated feed and ISO 22000 food safety management for feed; consistency of the oil suspension is checked with a Hegman grind gauge at ≤50 µm to avoid nozzle clogging. Compatibility with high-peroxide oils should be verified before production because hydroperoxides may accelerate andrographolide degradation in the finished coated pellet.